A Randomised, Double-blind, Placebo-controlled Parallel Group Phase III Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Progressive Pulmonary Fibrosis
Latest Information Update: 03 Apr 2026
At a glance
- Drugs HSK 44459 (Primary)
- Indications Pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Haisco Pharmaceutical Group
Most Recent Events
- 03 Apr 2026 New trial record